Lyell Immunopharma

$6.04 0.00% ($0.00)

Get ready to invest

About Lyell Immunopharma

Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). It offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. It utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

Popular Stocks	Price	Change
AMC Entertainment AMC	$20.57 0.44%	0.44%
AT&T T	$27.18 1.42%	1.42%
AMD AMD	$136.88 3.12%	3.12%
Nvidia NVDA	$269.42 1.38%	1.38%
FuelCell FCEL	$4.83 0.82%	0.82%
Micron Technology MU	$97.36 1.82%	1.82%
Ford F	$25.19 0.68%	0.68%
Apple AAPL	$173.07 0.51%	0.51%
NIO NIO	$30.95 1.54%	1.54%